Deerfield Management Company, L.P. (Series C) Immuno Gen, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

  • $5.38 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$4.55 - $6.31 $33.6 Million - $46.6 Million
-7,381,891 Reduced 53.72%
6,358,314 $31.5 Million
Q3 2022

Nov 14, 2022
SELL
$4.48 - $6.47 $5.74 Million - $8.28 Million
-1,280,285 Reduced 8.52%
13,740,205 $65.7 Million
Q2 2022

Aug 15, 2022
BUY
$3.15 - $5.76 $36.4 Million - $66.5 Million
11,549,815 Added 332.78%
15,020,490 $67.6 Million
Q1 2022

May 16, 2022
BUY
$4.26 - $7.48 $14.8 Million - $26 Million
3,470,675 New
3,470,675 $16.5 Million

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email